Success Metrics

Clinical Success Rate

87.5%

Based on 7 completed trials

Completion Rate

88%(7/8)

Active Trials

4(29%)

Results Posted

71%(5 trials)

Terminated

1(7%)

Phase Distribution

Ph phase_2

36%

Ph phase_3

21%

Ph phase_1

43%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution14 total trials

Phase 1Safety & dosage

6(42.9%)

Phase 2Efficacy & side effects

5(35.7%)

Phase 3Large-scale testing

3(21.4%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

87.5%

7 of 8 finished

Non-Completion Rate

12.5%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(5)

Completed(7)

Terminated(1)

Other(1)

Detailed Status

Completed7

Recruiting4

Not yet recruiting1

unknown1

Terminated1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

87.5%

Most Advanced

Phase 3

Trials by Phase

Phase 16 (42.9%)

Phase 25 (35.7%)

Phase 33 (21.4%)

Trials by Status

not_yet_recruiting17%

recruiting429%

unknown17%

terminated17%

completed750%

Recent Activity

4 active trials

Showing 5 of 14

completedphase_2

Study of Bomedemstat in Participants With Essential Thrombocythemia (IMG-7289-CTP-201/MK-3543-003)

NCT04254978

recruitingphase_3

Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)

NCT06456346

recruitingphase_3

A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)

NCT06079879

recruitingphase_3

A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)

NCT06351631

completedphase_1

A Study of Bomedemstat (MK-3543) in Participants With Mild or Moderate Hepatic Impairment (MK-3543-023)

NCT07049939

View all 14 trials

Clinical Trials (14)

Showing 14 of 14 trials

NCT04254978Phase 2

Study of Bomedemstat in Participants With Essential Thrombocythemia (IMG-7289-CTP-201/MK-3543-003)

Completed

NCT06456346Phase 3

Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)

Recruiting

NCT06079879Phase 3

A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)

Recruiting

NCT06351631Phase 3

A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)

Recruiting

NCT07049939Phase 1

A Study of Bomedemstat (MK-3543) in Participants With Mild or Moderate Hepatic Impairment (MK-3543-023)

Completed

NCT07424950Phase 2

Bomedemstat (IMG-7289) in Combination With Momelotinib in Patients With Myelofibrosis

Not Yet Recruiting

NCT05597306Phase 1

Venetoclax and Bomedemstat in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Recruiting

NCT05223920Phase 2

An Extension Study of Bomedemstat (IMG-7289/MK-3543) in Participants With Myeloproliferative Neoplasms (IMG-7289-CTP-202/MK-3543-005)

Completed

NCT05558696Phase 2

A Study of Bomedemstat (MK-3543) in Participants With Polycythemia Vera (MK-3543-004)

Completed

NCT06596668Phase 1

Drug-Drug Interaction Study of Bomedemstat and Carbamazepine in Healthy Adult Participants (MK-3543-020)

Completed

NCT05191797Phase 1

Bomedemstat and Maintenance Immunotherapy for Treatment of Newly Diagnosed Extensive Stage Small Cell Lung Cancer

Terminated

NCT03136185Phase 1

Bomedemstat (IMG-7289/MK-3543) in Participants With Myelofibrosis (IMG-7289-CTP-102/MK-3543-002)

Completed

NCT02842827Phase 1

A Study of Bomedemstat (IMG-7289/MK-3543) With and Without ATRA, in Participants With Advanced Myeloid Malignancies (IMG-7289-CTP-101/MK-3543-001)

Completed

NCT05569538Phase 2

Bomedemstat (IMG-7289) Plus Ruxolitinib for Myelofibrosis

Unknown

All 14 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 14